SOURCE: SciClone Pharmaceuticals, Inc.

October 25, 2006 06:30 ET

SciClone Pharmaceuticals to Present at the Rodman & Renshaw Healthcare Conference

SAN MATEO, CA -- (MARKET WIRE) -- October 25, 2006 -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that it will present at the Rodman & Renshaw Healthcare Conference on Monday, November 6, 2006 at 12:50 pm EST.

To access the live audio webcast of the presentation, log on through a link located in the Investor Relations section of SciClone's website at www.sciclone.com. A replay of the webcast will be available until November 27, 2006.

About SciClone

SciClone Pharmaceuticals is a biopharmaceutical company engaged in the development of therapeutics to treat life-threatening diseases. SciClone's lead product ZADAXIN is currently being evaluated in late-stage clinical trials for the treatment of malignant melanoma and hepatitis C. ZADAXIN is approved for sale in select markets internationally, most notably in China where SciClone has an established sales and marketing operation. SciClone's strategy is to leverage its advantage in China by in-licensing or acquiring the marketing rights to other products, such as the DC Bead distribution rights, to market in this rapidly growing pharmaceutical market. SciClone's other drug development candidate is SCV-07, currently in early clinical development in the U.S. for the treatment of viral and other infectious diseases. For more information about SciClone, visit www.sciclone.com.

Contact Information

  • Corporate contact:
    Richard Waldron
    Chief Financial Officer
    SciClone Pharmaceuticals, Inc.
    650-358-3437